XSHE
300254
Market cap352mUSD
Oct 09, Last price
9.28CNY
1D
1.09%
1Q
12.62%
Jan 2017
-51.89%
IPO
-22.76%
Name
Shanxi C&Y Pharmaceutical Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ShanXi C&Y Pharmaceutical Group Co., Ltd. is a global pharmaceutical enterprise dedicated to the research, development, production, and distribution of a diverse range of medicines. Its operations span key markets including China, the United States, and Hong Kong, alongside other international regions. The company's extensive product catalog features specialized solutions for maternal and infant care, urological health, and infectious diseases, as well as traditional Chinese remedies and dermatological treatments. Additionally, it diversifies its offerings with tea bag products. Founded in 2005, the organization underwent a name change in September 2014, evolving from Shanxi C&Y Pharmaceutical Co., Ltd. to its current designation. ShanXi C&Y Pharmaceutical Group Co., Ltd. maintains its corporate headquarters in Shanghai, China.
Key people
Qun Zhao
President, Director · since 2021
Hairong Zhong
Vice Chairman of the Board · since 2021
Yanjie He
Chief Financial Officer · since 2018
Kairui Luo
Vice President · since 2024
Han Yin
Vice President · since 2024
Yingmin Yu
Chief Engineer · since 2016
Lequn Huang
Chairman of the Board · since 2021
Junxian Yu
Vice President, Secretary of the Board · since 2026
Hao Gao
Independent Director · since 2020
Dong Huang
Independent Director · since 2026
Tao Ju
Independent Director · since 2020
Independent Director · since 2022
Jinfeng Wu
Independent Director · since 2026
Independent Director · since 2026
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||